HOME >> BIOLOGY >> NEWS
Braunschweig Prize 2003 for Molecular Cancer Therapy

Ten years ago the medic began working with the compound Imatinib that works against chronic myeloid leukemia (CML) and is commercially known as Glivec. Glivec blocks a protein that triggers the uncontrolled reproduction of white blood cells. "The name Brian Druker has become synonymous with a breakthrough in cancer therapy," said Braunschweig's mayor and chairman of the jury, Dr. Gert Hoffmann on the 8th of July after the vote of the council. Every year approximately 1700 people in Germany fall ill with CML. Some of the first patients to be treated with Glivec came from Germany.

Druker received his M.D. in 1981 from the University of California in San Diego. At Harvard Medical School he specialized in cancer research. Since 1993, Druker leads leukemia research at the Oregon Health & Science University Cancer Institute in Portland (USA). He is Investigator of the Howard Hughes Medical Institute and JELDWEN Chair of Leukemia Research. On the 27th of October he will accept the Braunschweig prize at the congress "Life in Tomorrow's World."

The American cancer researcher Prof. Dr. Brian Druker will be recognised for his research into molecular cancer ther-apy with the 50,000 Euro Braunschweig Prize, the highest research prize from a German city.

The 48-year-old medic is regarded as the pathfinder of the first tailor-made pill for the treatment of cancer. Ten years ago, in collaboration with the pharmaceutical company No-vartis, he identified the compound Imatinib, which in the meantime has become commercially available as Glivec. In contrast to chemotherapy that attacks both healthy and diseased cells, Imatinib targets a single protein that trig-gers the uncontrolled growth of white blood cells in chronic myeloid leukemia (CML). Every year approximately 1700 people in Germany fall ill with this blood cancer.

A recent study involving 1006 patients, comparing Glivec to standard therapy for CML, led by Druker, had to be stopped early because
'"/>

Contact: Jrgen Sperber
juergen.sperber@braunschweig.de
49-531-470-2212
Stadtverwaltung Braunschweig
8-Jul-2003


Page: 1 2

Related biology news :

1. Half-million dollar landmark achieved for the Methuselah Mouse Prize
2. Winner of 2004 EMBO Science Writing Prize announced
3. Fox Chase Cancer Centers Alfred Knudson Jr. named 2004 Kyoto Prize winner
4. Stuart Lipton honored with Jung Prize for Medicine
5. 2004 Max Planck Research Prize for Martin Vingron and Eugene W. Myers
6. Scripps research scientist wins 2004 Koch Prize
7. Ohio State wetlands professor wins prestigious Water Prize
8. Tony Hunter and Raymond N. DuBois awarded Landon-AACR Prizes for Cancer Research
9. Leibniz Prizewinners 2004
10. Roderick MacKinnon wins 2003 Nobel Prize in Chemistry
11. Illinois professor wins Nobel Prize

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Braunschweig Prize for Molecular Cancer Therapy

(Date:7/30/2014)... is a subject of major interest in neuroscience. ... during the distinct stages of Wallerian degeneration: transcription ... dedifferentiation. Although gene expression responses in the distal ... injury are known, differences in gene expression between ... Dengbing Yao and co-workers from Nantong University, China ...
(Date:7/30/2014)... cells can develop into a multitude of cells types. Researchers ... the specific types of mature cells that make up the ... key seems to be long chains of sugars that dangle ... at the University of California, San Diego, has created synthetic ... can be more easily manipulated to direct the process, they ...
(Date:7/30/2014)... high-resolution map of the carbon stocks stored on ... new and improved methodology used to make the ... carbon economies. The new carbon map also ... provides the critical input to studies of deforestation ... enforcement purposes. The technique includes the determination of ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
(Date:7/30/2014)... FRANCISCO , July 30, 2014 ... Congress evaluated the safety and efficacy of CSL ... rejection following kidney transplants in highly sensitized patients. ... inhibitor of the complement system. The ... in significant increases in the levels of complement ...
(Date:7/30/2014)... AZ (PRWEB) July 30, 2014 Sales ... the launch of blended sales training programs for companies ... sales training programs used by thousands of salespeople over ... blended sales training program can be customized to address ... , The blended sales training program consists ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Vycom announces ... of products, designed to meet Factory Mutual (FM) 4910 ... materials such as wet benches, process tools, fume hoods, ... safety and damage to semiconductor wafers used in electronic ... a flame-retardant PVC solution with excellent workability and superior ...
(Date:7/30/2014)... , July 30, 2014   Epic Sciences, ... and develops novel diagnostics to personalize and advance the ... of Gregory T. Lucier as chairman of ... and CEO of Life Technologies (formerly Invitrogen). Mr. Lucier ... Epic commercializes its circulating rare cell analysis platform with ...
Breaking Biology Technology:Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3
Cached News: